Litigation Details for Intercept Pharmaceuticals, Inc. v. Optimus Pharma Pvt. Ltd. (D. Del. 2020)

Intercept Pharmaceuticals, Inc. v. Optimus Pharma Pvt. Ltd. (D. Del. 2020)

Docket		Date Filed	2020-09-11
Court	District Court, D. Delaware	Date Terminated	2023-01-17
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,047,117; 10,052,337; 10,174,073; 7,138,390; 9,238,673
Link to Docket	External link to docket

Details for Intercept Pharmaceuticals, Inc. v. Optimus Pharma Pvt. Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2020-11-11	13	SO ORDERED	Stipulation to Substitute U.S. Patent No. RE48,286 for U.S. Patent No. 7,138,390. Signed by Judge Maryellen…2020 17 January 2023 1:20-cv-01215 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-11-19	17	Complaint - Amended	the ’673 patent”); 10,047,117 (filed Nov. 20, 1 The RE286 Patent is a reissue of U.S. Patent No. 7,138,390…or Non-Infringement for U.S. Patent Nos. 7,138,390; 9,238,673; 10,047,117; 10,052,337; and 10,174,073 …073 patent”); and 10,758,549 (filed Feb. 11, 2020) (“the ’549 patent”) (collectively the “patents-in-… 1. This action for patent infringement, brought pursuant to the patent laws of the United States… expiration of U.S. Patent Nos. RE48,286 (filed June 21, 2019) (“the RE286 patent”);1 9,238,673 (filed	External link to document
2020-11-19	18	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s)RE48,286; 9,238,673; 10,047,117; 10,052,…11 September 2020 1:20-cv-01215 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document